Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis

Abstract Background Clinical efficacy of immune checkpoint inhibitors (ICIs) for non-small cell lung cancer (NSCLC) with uncommon histology (uNSCLC) is unknown. Methods Patients with NSCLC treated with ICI monotherapy between January 2014 and December 2018 in 10 Japanese hospitals were retrospective...

Full description

Bibliographic Details
Main Authors: Koichi Miyashita, Masato Karayama, Yusuke Inoue, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Noriyuki Enomoto, Yutaro Nakamura, Masato Kono, Takashi Matsui, Mitsuru Niwa, Keigo Koda, Mikio Toyoshima, Sayomi Matsushima, Shun Matsuura, Kazuhiro Asada, Masato Fujii, Hideki Kusagaya, Hiroyuki Matsuda, Naoki Inui, Takafumi Suda
Format: Article
Language:English
Published: BMC 2021-10-01
Series:BMC Pulmonary Medicine
Subjects:
Pleomorphic carcinoma
Large cell neuroendocrine carcinoma
Not otherwise specified
Programmed death-1
Programmed death ligand-1
Online Access:https://doi.org/10.1186/s12890-021-01681-6

Internet

https://doi.org/10.1186/s12890-021-01681-6

Similar Items